Objective To update evidence‐based medicine recommendations for treating nonmotor
symptoms in Parkinson's disease (PD). Background The International Parkinson and …

The treatment of central nervous system (CNS) malignancies, including brain cancers, is
limited by a number of obstructions, including the blood-brain barrier (BBB), the …

Introduction This registry evaluated the 24-month safety and efficacy of levodopa-carbidopa
intestinal gel (LCIG) treatment in advanced Parkinson's disease (PD) patients under routine …

Apathy, depression, and anxiety are among the most important non-motor signs of
Parkinson's disease (PD). This may be encountered at early stages of illness and represent …

Objective To conduct a scoping review of the literature on apathy in Parkinson's disease
(PD), to better understand how apathy in Parkinson's disease is diagnosed, treated and …

Health-related quality of life (HRQoL) is defined as “the perception and evaluation by
patients themselves of the impact caused on their lives by the disease and its …

Pain is a troublesome nonmotor symptom of Parkinson's disease (PD). This double‐blind
exploratory pilot study (NCT01744496) was the first to specifically investigate the effect of a …

Neuropsychiatric symptoms are common and disabling in PD. Their neurobiological bases
are complex, partly because of the disease itself and partly because of the dopaminergic …

Pain is a common and disabling non-motor symptom (NMS) of Parkinson's disease (PD),
which occurs through the course of the disease, often unrecognized and undertreated. For …

A caregiver's all‐too‐familiar narrative‐“He doesn't think through what he does, but mostly
he does nothing.” Apathy and impulsivity, debilitating and poorly understood, commonly co …